Citation Impact
Citing Papers
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Infectious enveloped RNA virus antigenic chimeras.
1992 StandoutNobel
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
2001
Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains
1991 StandoutNobel
B1b Lymphocytes Confer T Cell-Independent Long-Lasting Immunity
2004 StandoutNobel
Role of Transforming Growth Factor β in Human Disease
2000 Standout
Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli
1989 StandoutNatureNobel
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
2019 StandoutNatureNobel
Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
1997 StandoutNobel
Ribosome-inactivating proteins from plants
1993
Retargeting serum immunoglobulin with bispecific diabodies
1997 StandoutNobel
Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategy
1999
Identification of the residues in human CD4 critical for the binding of HIV
1989 StandoutNobel
Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides
1991
Cancer Statistics, 2006
2006 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
The recognition event between virus and host cell receptor: a target for antiviral agents
1990
Vascular targeting—a new approach to the therapy of solid tumors
1994
Molecular basis of human CD22 function and therapeutic targeting
2017
Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
1996 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome
1998
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
2005 StandoutNobel
CD4: Collaborator in immune recognition and HIV infection
1990 StandoutNobel
Stimulated Release of Size‐Selected Cargos in Succession from Mesoporous Silica Nanoparticles
2012 StandoutNobel
Signal transduction by lymphocyte antigen receptors
1994 Standout
Identification and expansion of human colon-cancer-initiating cells
2006 StandoutNature
Biodegradable block copolymers as injectable drug-delivery systems
1997 StandoutNature
CD22 as a target of passive immunotherapy
2003
Crystal structure of an HIV-binding recombinant fragment of human CD4
1990 StandoutNatureNobel
Calmodulin as a Versatile Tag for Antibody Fragments
1995 StandoutNobel
Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice
2003
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
1993 Science
Making antibody fragments using phage display libraries
1991 StandoutNatureNobel
Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [γ-32P]-ATP
1996 StandoutNobel
Open sandwich ELISA: A novel immunoassay based on the interchain interaction of antibody variable region
1996 StandoutNobel
In-cell PCR from mRNA: amplifying and linking the rearranged immunoglobulin heavy and light chain V-genes within single cells
1992 StandoutNobel
Recombinant Toxins for Cancer Treatment
1991 Science
Molecular characteristics of recombinant human CD4 as deduced from polymorphic crystals.
1990 StandoutNobel
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future [published erratum appears in Blood 1991 Dec 15;78(12):3330]
1991
Tissue Engineering
1993 StandoutScience
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Polymeric Systems for Controlled Drug Release
1999 Standout
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
1993
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study
1995
Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).
1991
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes
2008
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
1994
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.
1995
Tumor Lectinology: At the Intersection of Carbohydrate Chemistry, Biochemistry, Cell Biology, and Oncology
1988
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Alphavirus-based expression vectors: strategies and applications.
1996 StandoutNobel
Escherichia coli Secretion of an Active Chimeric Antibody Fragment
1988 Science
Drug Discovery: A Historical Perspective
2000 StandoutScience
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
1998 StandoutScience
Generation of a Complement-Independent Bactericidal IgM against a Relapsing Fever Borrelia
2004
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
1996
Making Antibodies by Phage Display Technology
1994 StandoutNobel
Single-Chain Immunotoxins Directed at the Human Transferrin Receptor Containing Pseudomonas Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv)
1991
"Diabodies": small bivalent and bispecific antibody fragments.
1993 StandoutNobel
Potent and specific antitumor effects of an anti-CD22–targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma
2001
Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin
1994
Growth Factors and Cancer
1991 StandoutScience
Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation.
1992 StandoutNobel
Inhibitors of human immunodeficiency virus integrase.
1993 StandoutNobel
Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.
1990
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
2005
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
1989 StandoutNobel
Erythrocyte P Antigen: Cellular Receptor for B19 Parvovirus
1993 StandoutScience
Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.
1992 StandoutNobel
Engineering Chemical Reactivity on Cell Surfaces Through Oligosaccharide Biosynthesis
1997 StandoutScienceNobel
Monoclonal Antibodies in Diagnosis and Therapy
1991 Science
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
2014 StandoutNobel
New Methods of Drug Delivery
1990 Science
Works of Mark Till being referenced
Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers
1990
The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies
1989
Evaluation of four CD22 antibodies as ricin a chain‐containing immunotoxins for the in vivo therapy of human B‐cell leukemias and lymphomas
1988
Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain
1990
Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function.
1990
HIV-Infected Cells Are Killed by rCD4-Ricin A Chain
1988 Science
Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
1988
Phase I immunotoxin trial in patients with B-cell lymphoma.
1991
Redesigning Nature's Poisons to Create Anti-Tumor Reagents
1987 Science